Biosyntia raise 4 mEUR to advance its proprietary technology and product pipeline
Biosyntia has today announced a Series A investment in the company of 4 million euros from Sofinnova Partners, a new investor, and Novo Seeds, an existing investor. The investment will allow the company continued developments of its lead products and bring it closer to commercialisation.
“Biosyntia has a unique, world-class microbe engineering technology allowing it to rapidly develop replacements for oil-derived products consumed in our daily life. With an extraordinary team and large, growing market opportunity they have all the ingredients for success”, says Joško Bobanović, partner with Sofinnova Partners’ Industrial Biotechnology Fund.
Read how the CSO, Hans Genee and the biotech entrepreneur Andreas Lausten formed Biosyntia
The entrepreneurs, Gene and Lausten tells about how they formed Biosyntia together with Morten Sommer, while they were all finishing their deegres. They hope to encourage and inspire young scientist and engineers to take part in startup, as it can be very educational. Genee mention the importance in creating a good team and get lots of feedback and advice.
Biosyntia participated among seven other selected companies, in the annual Connecting Bright Innovations 2017
Together with seven other finalist, Biosyntia was selected to pitch at the event, in front of a panel of experts. The expert panel received many applications from entrepreneuers and innovators from around the world, but only invited eight companies to pitch in Delft. The panel was impressed by the high standard and was inspired by the passion, drive and energy.
Biosyntia and FGen to Collaborate on Development of Vitamin Production Strain
In the collaboration Biosyntia will use its multiplex engineering tools for the simultaneous modification of several targets identified as bottlenecks in the vitamin pathway. The resulting highly diverse libraries will be analyzed by FGen’s proprietary nanoliter-reactor platform and candidates with improved productivities will be isolated. The final goal is substitution of the current polluting chemical synthesis route by a sustainable, bio-based vitamin production process.
Biosyntia technology applied to novel gene discovery – featured in Nature Chemical Biology
Together with researchers from the Center for Biosustainability at the Technical University of Denmark, Biosyntia developed a synthetic selection system for solute transporters and used the tehchnology to mine metagenomes for novel gene functions. The study demonstrates how Biosyntia can perform synthetic selections to accelerate R&D discoveries. (Published October 2016)
Biosyntia co-founders selected among Top 10 European Biotech Entrepreneurs under 30 in 2016
In September 2016, Hans Genee and Andreas Laustsen were selected among Europes 10 most inspiring innovators under 30. Thanks to Labiotech.eu!
Among the Most Innovative Industrial Biotech SMEs in Europe
In September 2016, Biosyntia was recognized by EuropaBio as one of the Most Innovative Biotech SMEs in Europe within biotechnology. The initiative recognizes highly innovative small and medium sized enterprises in Europe that have developed novel ways of meeting our societal, technical, and environmental problems through the application of biotechnology.
Half a million base pairs of DNA awarded to support cell factory development
September 2016. Gen9, Inc., a pioneer in the development of scalable technologies for synthesizing and assembling DNA, announced the winners of its fourth annual G-Prize contest. Biosyntia was selected by an independent panel of judges for a proposal showcasing creative usage of synthetic biology to accelerate research and product development. Biosyntia will receive 500,000 base pairs of synthetic DNA manufactured on Gen9’s BioFab® platform.
Using big “bio-data” to design better cell factories
In spring 2016, the European Commission awarded 6.3 million Euros to a four-year collaborative project on data-driven design of cells and microbial communities for applications ranging from human health to sustainable production of chemicals. The project, called DD-DeCaF (Bioinformatics Services for Data-Driven Design of Cell Factories and Communities) brings together leading academic partners from five European universities with five innovative European companies to address the challenge of building a comprehensive design tool.
Seed Investment To Establish a Bio-based Vitamin Production Platform
In May 2015 Biosyntia ApS completed a DKK 12.5 M financing round with Novo Seeds as lead investor. “We invest worldwide and only in the companies with unique differentiators and competitive edge. We believe that Biosyntia has the potential to build a world leading synthetic biology platform and accordingly can attract international strategic partners and investors”, says Søren Carlsen, Managing Partner of Novo Ventures and Novo Seeds.
Among the 25 most promising Nordic cleantech start-ups
February 2015. We are proud to be among the 25 most promising cleantech start-ups in the Nordic awarded by the Nordic Cleantech Open.
Best Life Science Company Presentation
In November 2014, Biosyntia was again awarded Best Company Presentation at the Nordic Venture Forum in Copenhagen, Denmark. The Nordic Venture Forum promotes the innovative, attractive, and rewarding investment environment of the Nordic and Baltic countries.
Top 5 Most Innovative Biotech SME in Europe
In October 2014, Biosyntia was recognized by EuropeBio as one of the Top 5 Most Innovative SMEs in Europe within biotechnology. EuropaBio is a trade association with the mission to create an innovative and dynamic biotechnology industry in Europe by communicating the benefits of biotech to all corners of society.
Funding received through the PROMYS consortium
In December 2013, Biosyntia as a partner in the PROMYS consortium received substantial funding through the EU’s FP7 programme. The consortium focuses on synthetic pathway construction, cell factory optimization, and control of populations during fermentation.
Best Life Science Company Presentation
In November 2013, Biosyntia was awarded Best Life Science Company Presentation at the Nordic Venture Forum in Copenhagen, Denmark. The Nordic Venture Forum promotes the innovative, attractive, and rewarding investment environment of the Nordic and Baltic countries.
A Pre-Seed Grant to Accelerate Commercialization
In June 2013, Biosyntia received a Pre-Seed Grant from Novo A/S. Novo A/S is a private company fully owned by the Novo Nordisk Foundation and responsible for managing the Foundation’s assets. As holding company for the Novo Group, Novo A/S is the major shareholder in the publicly listed companies Novo Nordisk A/S and Novozymes A/S.
Among the 10 Best Startup Stories in Europe
In June 2013, Biosyntia was chosen as one of the 10 best startup stories by Europe Unlimited. Through networking entrepreneurs, investors, corporations, researchers, and advisors Europe Unlimited helps Europe’s dynamic technology innovators become World leaders in their field.
Among the Top 10 Life Science Companies
In December 2012, Biosyntia was among the top 10 presenting life science companies at the European Venture Summit (EVS) in Berlin. EVS finds, evaluates, and awards world-class innovative companies with the potential to dramatically impact their industry and contribute to increasing European competitiveness and growth.
Best Cleantech Idea Globally
In November 2012, Biosyntia was awarded Best Global Idea at Cleantech Open in San José, California, thereby securing a USD 100,000 prize. The Cleantech Open runs the World’s largest accelerator for cleantech startups. Their mission is to find, fund, and foster entrepreneurs with big ideas that address today’s most urgent energy, environmental, and economic challenges.
Among the Top 5 Startups in the World
In November 2012, Biosyntia was among the top 5 finalists in the Intel Global Challenge. The Intel Global Challenge at UC Berkeley is the largest startup competition globally. Here, the best of more than 140,000 participating engineers and scientists present how they plan to make the World a better place through their innovations and entrepreneurial skills.
Best European Startup
In September 2012, Biosyntia was awarded Best European Startup at the Intel Business Challenge in Sopot, Poland, thereby securing a USD 25,000 prize. The Intel Business Challenge is the largest startup competition in Europe with more than 40,000 participants.
Best Company Presentation
In September 2012, Biosyntia was awarded Best Presentation at the European Food Venture Forum in Aarhus, Denmark. The European Food Venture Forum offers a unique platform for food high-growth companies, technology corporations, and international investors to exchange knowledge and build lasting business co-operations.
An Exploratory Pre-Seed Grant to Accelerate Commercialization
In June 2012, Biosyntia received an Exploratory Pre-Seed Grant of USD 85,000 from Novo A/S. Novo A/S is a private company fully owned by the Novo Nordisk Foundation and responsible for managing the Foundation’s assets. As holding company for the Novo Group, Novo A/S is the major shareholder in the publicly listed companies Novo Nordisk A/S and Novozymes A/S.
Most Promising Greentech
In June 2012, Biosyntia was awarded Most Promising Greentech GRØN DYST (GREEN BATTLE) at the Technical University of Denmark, thereby securing USD 10,000. The GRØN DYST Student Conference is a unique opportunity for DTU students to present their projects to fellow students, their teachers, DTU alumni, as well as invited guests, such as business people and politicians.
Best Cleantech Startup in Denmark
In June 2012, Biosyntia was awarded Best Cleantech in Denmark at the Venture Cup Startup Competition in Copenhagen, thereby securing USD 10,000. Venture Cup is one of Europe’s largest and most trusted non-profits to help make startups happen.
Be part of the ride
We believe that innovation will help drive the world into a greener, bio-based future. We have a passion for this challenge and for each other. Contact us if you want to be part of the future with us.